Connection

William Creasman to Middle Aged

Back to Details
This is a "connection" page, showing publications William Creasman has written about Middle Aged.
William Creasman
Connection Strength
0.731
Middle Aged
  1. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2017 06; 145(3):519-525.
    View in: PubMed
    Score: 0.041
  2. Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? Gynecol Oncol. 2016 08; 142(2):278-82.
    View in: PubMed
    Score: 0.038
  3. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S105-43.
    View in: PubMed
    Score: 0.020
  4. Breast cancer: the role of hormone therapy. Semin Reprod Med. 2005 May; 23(2):167-71.
    View in: PubMed
    Score: 0.018
  5. Carcinoma of the vulva. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:7-26.
    View in: PubMed
    Score: 0.016
  6. Carcinoma of the vagina. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:27-39.
    View in: PubMed
    Score: 0.016
  7. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:79-118.
    View in: PubMed
    Score: 0.016
  8. Gestational trophoblastic diseases. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:167-74.
    View in: PubMed
    Score: 0.016
  9. WHI: Now that the dust has settled: a commentary. Am J Obstet Gynecol. 2003 Sep; 189(3):621-6.
    View in: PubMed
    Score: 0.016
  10. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003 May; 188(5):1174-6.
    View in: PubMed
    Score: 0.015
  11. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jan; 84(1):32-5.
    View in: PubMed
    Score: 0.014
  12. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001 Jul; 82(1):7-10.
    View in: PubMed
    Score: 0.014
  13. The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. Gynecol Oncol. 2021 03; 160(3):660-668.
    View in: PubMed
    Score: 0.013
  14. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol. 2001 Jan; 184(2):64-9.
    View in: PubMed
    Score: 0.013
  15. A survey of hospital management practices for vulvar melanoma. J Am Coll Surg. 1999 Jun; 188(6):670-5.
    View in: PubMed
    Score: 0.012
  16. An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med. 1999 Jun-Aug; 44(4):186-92.
    View in: PubMed
    Score: 0.012
  17. HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat. 1999; 4(3):217-20; discussion 221-5.
    View in: PubMed
    Score: 0.011
  18. Is there an association between hormone replacement therapy and breast cancer? J Womens Health. 1998 Dec; 7(10):1231-46.
    View in: PubMed
    Score: 0.011
  19. The National Cancer Data Base report on cancer of the vagina. Cancer. 1998 Sep 01; 83(5):1033-40.
    View in: PubMed
    Score: 0.011
  20. Receipt of adjuvant endometrial cancer treatment according to race: an?NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol. 2018 11; 219(5):459.e1-459.e11.
    View in: PubMed
    Score: 0.011
  21. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol. 2018 01; 148(1):174-180.
    View in: PubMed
    Score: 0.011
  22. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer. 2018 03 15; 142(6):1102-1115.
    View in: PubMed
    Score: 0.011
  23. The National Cancer Data Base report on early stage invasive vulvar carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1997 Aug 01; 80(3):505-13.
    View in: PubMed
    Score: 0.010
  24. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 1997 Aug; 66(2):171-8.
    View in: PubMed
    Score: 0.010
  25. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
    View in: PubMed
    Score: 0.010
  26. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
    View in: PubMed
    Score: 0.010
  27. Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017 04 01; 123(7):1144-1155.
    View in: PubMed
    Score: 0.010
  28. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
    View in: PubMed
    Score: 0.010
  29. The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):264-9.
    View in: PubMed
    Score: 0.009
  30. Replacement therapy for breast cancer survivors. A pilot study. Cancer. 1995 Nov 15; 76(10 Suppl):2075-8.
    View in: PubMed
    Score: 0.009
  31. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.009
  32. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1995 Jun; 57(3):412-6.
    View in: PubMed
    Score: 0.009
  33. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol. 1993 Aug; 11(8):1523-8.
    View in: PubMed
    Score: 0.008
  34. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
    View in: PubMed
    Score: 0.008
  35. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992 Apr; 79(4):490-7.
    View in: PubMed
    Score: 0.007
  36. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol. 1991 Dec; 78(6):1027-32.
    View in: PubMed
    Score: 0.007
  37. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol. 1991 Jan; 40(1):42-5.
    View in: PubMed
    Score: 0.007
  38. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec; 39(3):239-43.
    View in: PubMed
    Score: 0.007
  39. Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol. 1990 Jun; 37(3):390-5.
    View in: PubMed
    Score: 0.006
  40. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989 Oct; 7(10):1462-8.
    View in: PubMed
    Score: 0.006
  41. The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma. Eur J Obstet Gynecol Reprod Biol. 2008 Dec; 141(2):163-8.
    View in: PubMed
    Score: 0.006
  42. A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. A preliminary report of a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1988 Jul; 159(1):87-94.
    View in: PubMed
    Score: 0.006
  43. Combined adverse effect of African American race and deep stromal invasion on survival following radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2008 Aug; 199(2):196.e1-7.
    View in: PubMed
    Score: 0.006
  44. Absorbable synthetic mesh (910-polyglactin) intestinal sling to reduce radiation-induced small bowel injury in patients with pelvic malignancies. Gynecol Oncol. 1988 Mar; 29(3):283-9.
    View in: PubMed
    Score: 0.005
  45. Absorbable synthetic mesh (polyglactin 910) for the formation of a pelvic "lid" after radical pelvic resection. Am J Obstet Gynecol. 1988 Jan; 158(1):158-61.
    View in: PubMed
    Score: 0.005
  46. Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. Arch Surg. 1988 Jan; 123(1):42-5.
    View in: PubMed
    Score: 0.005
  47. Uterine leiomyomas with retroperitoneal lymph node involvement. South Med J. 1987 Oct; 80(10):1320-2.
    View in: PubMed
    Score: 0.005
  48. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug; 106(2):362-9.
    View in: PubMed
    Score: 0.005
  49. Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. Gynecol Oncol. 1987 Feb; 26(2):160-8.
    View in: PubMed
    Score: 0.005
  50. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol. 1987 Feb; 69(2):151-5.
    View in: PubMed
    Score: 0.005
  51. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol. 1987 Jan; 26(1):11-8.
    View in: PubMed
    Score: 0.005
  52. Radical hysterectomy as therapy for early carcinoma of the cervix. Am J Obstet Gynecol. 1986 Nov; 155(5):964-9.
    View in: PubMed
    Score: 0.005
  53. Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S145-60.
    View in: PubMed
    Score: 0.005
  54. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S161-92.
    View in: PubMed
    Score: 0.005
  55. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S193-203.
    View in: PubMed
    Score: 0.005
  56. Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S29-42.
    View in: PubMed
    Score: 0.005
  57. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S43-103.
    View in: PubMed
    Score: 0.005
  58. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S7-27.
    View in: PubMed
    Score: 0.005
  59. Superior vena cava syndrome associated with gynecologic malignancy. Gynecol Oncol. 1986 Jan; 23(1):59-64.
    View in: PubMed
    Score: 0.005
  60. Should symptomatic menopausal women be offered hormone therapy? MedGenMed. 2006; 8(2):1 p preceding 35.
    View in: PubMed
    Score: 0.005
  61. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1985 Jun 15; 152(4):418-23.
    View in: PubMed
    Score: 0.004
  62. Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases. Gynecol Oncol. 1985 Jun; 21(2):220-7.
    View in: PubMed
    Score: 0.004
  63. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol. 1985 Apr 01; 151(7):922-32.
    View in: PubMed
    Score: 0.004
  64. Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. Obstet Gynecol. 1984 Nov; 64(5):689-94.
    View in: PubMed
    Score: 0.004
  65. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1984 Jun; 7(3):257-60.
    View in: PubMed
    Score: 0.004
  66. Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet Gynecol. 1984 Feb; 63(2):145-9.
    View in: PubMed
    Score: 0.004
  67. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol. 1983 Oct 15; 147(4):369-75.
    View in: PubMed
    Score: 0.004
  68. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:41-78.
    View in: PubMed
    Score: 0.004
  69. Carcinoma of the Fallopian tube. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:119-33.
    View in: PubMed
    Score: 0.004
  70. Carcinoma of the ovary. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:135-66.
    View in: PubMed
    Score: 0.004
  71. Intracavitary Corynebacterium parvum for treatment of malignant effusions. Gynecol Oncol. 1983 Aug; 16(1):6-14.
    View in: PubMed
    Score: 0.004
  72. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol. 1983 Mar 01; 145(5):606-13.
    View in: PubMed
    Score: 0.004
  73. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol. 1983 Jan; 61(1):87-94.
    View in: PubMed
    Score: 0.004
  74. A trial of prophylactic cefamandole in extended gynecologic surgery. Obstet Gynecol. 1982 Mar; 59(3):309-14.
    View in: PubMed
    Score: 0.004
  75. Significant venous thromboembolism caused by pelvic lymphocysts: diagnosis and management. Gynecol Oncol. 1982 Feb; 13(1):136-43.
    View in: PubMed
    Score: 0.004
  76. Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. Gynecol Oncol. 1981 Dec; 12(3):319-27.
    View in: PubMed
    Score: 0.004
  77. The abnormal Pap smear--what to do next? Cancer. 1981 Jul 15; 48(2 Suppl):515-22.
    View in: PubMed
    Score: 0.003
  78. Conservative management of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1980 Mar; 23(1):281-91.
    View in: PubMed
    Score: 0.003
  79. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol. 1980 Mar; 55(3):363-70.
    View in: PubMed
    Score: 0.003
  80. Unusual metastasis in carcinoma of the cervix uteri. Surg Gynecol Obstet. 1979 May; 148(5):728-30.
    View in: PubMed
    Score: 0.003
  81. Operative management of early invasive epidermoid carcinoma of the vulva. Am J Obstet Gynecol. 1975 Oct 15; 123(4):349-55.
    View in: PubMed
    Score: 0.002
  82. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
    View in: PubMed
    Score: 0.002
  83. Paget's disease of the vulva. Gynecol Oncol. 1975 Jun; 3(2):133-48.
    View in: PubMed
    Score: 0.002
  84. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994 Apr; 170(4):974-9; discussion 979-80.
    View in: PubMed
    Score: 0.002
  85. Experience with a mass closure technique using continuous looped polyglyconate absorbable suture. J Am Coll Surg. 1994 Feb; 178(2):177-80.
    View in: PubMed
    Score: 0.002
  86. Efficacy of cryosurgical treatment of severe cervical intraepithelial neoplasia. Obstet Gynecol. 1973 Apr; 41(4):501-6.
    View in: PubMed
    Score: 0.002
  87. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15; 71(4 Suppl):1702-9.
    View in: PubMed
    Score: 0.002
  88. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993 Jan 15; 71(2 Suppl):606-14.
    View in: PubMed
    Score: 0.002
  89. Carcinoma in situ of the cervix. An analysis of 861 patients. Obstet Gynecol. 1972 Mar; 39(3):373-80.
    View in: PubMed
    Score: 0.002
  90. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992 Jan; 166(1 Pt 1):50-3.
    View in: PubMed
    Score: 0.002
  91. Running mass closure of abdominal wounds using absorbable looped suture. J Gynecol Surg. 1991; 7(2):107-10.
    View in: PubMed
    Score: 0.002
  92. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol. 1990 Apr; 75(4):684-9.
    View in: PubMed
    Score: 0.002
  93. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol. 1990 Feb; 75(2):249-54.
    View in: PubMed
    Score: 0.002
  94. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Dec; 35(3):314-20.
    View in: PubMed
    Score: 0.002
  95. Conservative surgical management of superficially invasive stage I vulvar carcinoma. Gynecol Oncol. 1989 Dec; 35(3):352-7.
    View in: PubMed
    Score: 0.002
  96. Pelvic exenteration: factors associated with major surgical morbidity. Gynecol Oncol. 1989 Oct; 35(1):93-8.
    View in: PubMed
    Score: 0.002
  97. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Apr; 33(1):68-70.
    View in: PubMed
    Score: 0.001
  98. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986 Oct; 46(10):5419-25.
    View in: PubMed
    Score: 0.001
  99. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 01; 57(9):1725-30.
    View in: PubMed
    Score: 0.001
  100. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986 Mar; 67(3):326-30.
    View in: PubMed
    Score: 0.001
  101. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer. 1985 Jul 15; 56(2):243-8.
    View in: PubMed
    Score: 0.001
  102. Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. Am J Obstet Gynecol. 1984 Oct 15; 150(4):437-9.
    View in: PubMed
    Score: 0.001
  103. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1984 May; 68(5):809-11.
    View in: PubMed
    Score: 0.001
  104. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983 Aug 15; 52(4):626-32.
    View in: PubMed
    Score: 0.001
  105. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. Am J Clin Oncol. 1983 Jun; 6(3):273-5.
    View in: PubMed
    Score: 0.001
  106. Risk of exogenous estrogen therapy and endometrial cancer. Am J Obstet Gynecol. 1980 May 01; 137(1):85-91.
    View in: PubMed
    Score: 0.001
  107. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol. 1979 Jul; 96(1):171-83.
    View in: PubMed
    Score: 0.001
  108. An alternate approach to early cancer of the vulva. Am J Obstet Gynecol. 1979 Apr 01; 133(7):825-32.
    View in: PubMed
    Score: 0.001
  109. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol. 1979 Mar 01; 133(5):537-47.
    View in: PubMed
    Score: 0.001
  110. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol. 1979 Mar 01; 133(5):525-36.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.